Deborah Mash is a neuroscientist, inventor, and one of the world’s foremost experts on the anti-addiction drug ibogaine. She is the CEO and Founder of DemeRx Inc., a clinical stage drug development company advancing ibogaine and its active metabolite noribogaine for the treatment of opioid use disorder. DemeRx has partnered with ATAI Life Sciences — a global biotech platform with a special focus on psychedelic medicine — to develop ibogaine for those suffering from opioid use disorder. Building on the extensive human data available around ibogaine, DemeRx and atai will submit Clinical Trial Applications for a Phase II study in opioid-dependent patients. This joint venture will develop screening procedures, dosing guidelines, and best practices for treating opioid use disorder following detoxification to ensure patient safety.